Ad Code: Ingrezza - Display Banners Condition Spotlight - Oct - ING Pref - 155682

Authors of a recent review outlined barriers to tardive dyskinesia diagnosis and how neurologists and psychiatrists can collaborate to optimize care.

Dr. Eiry Roberts discusses why clinicians should avoid anticholinergics in patients with tardive...

Several clinical trials have tested the efficacy and safety of valbenazine and deutetrabenazine in patients with TD.

Deep brain stimulation offers advantages such as adjustability, reversibility, and the potential for rapid and long-term improvement in tardive dyskinesia.

Annual training and reliable new tools can help physicians improve tardive dyskinesia screening and symptom measurement.

There are approximately 600,000 people in the US who are living with TD—65% of them have not been diagnosed.

The Tardive Dyskinesia Impact Scale complements the Abnormal Involuntary Movement Scale by combining clinician-rated and patient-reported perspectives.

The Extrapyramidal Symptom Rating Scale and an abbreviated version of the scale were both validated for measuring the impact of tardive dyskinesia.